COLLINSON
Collinson, a global leader in travel experience and loyalty programmes, has announced a strategic partnership with World Nomads, the global travel insurance provider, including the launch of a new Annual Multi-Trip (AMT) product in the UK & Ireland.
The new product range will enhance the customer experience with the addition of increased coverage limits and new benefits that apply to both annual and single-trip policies, as well as innovative parametric service, SmartDelayTM. These enhancements ensure that travellers are better protected against a wider range of travel-related issues and unexpected flight delays or cancellations.
As part of the partnership, Collinson will be responsible for underwriting the AMT product as well as providing World Nomad customers with the use of its new parametric product SmartDelay.
SmartDelay is a real-time, parametric product which provides customers with a range of benefits in the event of a flight disruption, for example, providing access to over 1500 airport lounges or alternative benefits such as spa, sleep pods and restaurant discounts for travellers experiencing flight delays. SmartDelay also gives traveller access to Air Doctor, which connects travellers with private doctors and medical advice in destinations where public health services may be overstretched and/or unable to treat international travellers.
This new partnership supports Collinson’s UK and European growth ambitions, allowing the company to underwrite business for World Nomads in the UK, Ireland, Germany, Denmark, Belgium and Holland, with more to follow.
Greg Lawson, Head of Travel Insurance at Collinson, said: “Given both Collinson and World Nomads are established and respected brands by travellers globally, our collaboration in developing products that deliver above and beyond what today’s travellers demand from their travel insurance, demonstrates our commitment in offering fair value, flexibility and choice. The synergies of our companies make our partnership stronger, given Collinson’s experience as a renowned travel underwriter and World Nomad’s commitment to offer innovative travel insurance. It’s a great time to bring exciting products to the travel market to drive our shared UK and European growth ambitions.”
World Nomads’ AMT policy offers comprehensive and cost-effective coverage for frequent international and domestic travellers, allowing for multiple trips within a one-year period under a single policy. Additionally, a higher age limit (up to 69 years) and free coverage for children (aged under 18) when travelling with adult relatives or friends applies, making the AMT policy ideal for multigenerational travel.
Jonathan Frankham, General Manager, UK and Europe, World Nomad, said: “Both the introduction of the AMT product and the integration of Collinson as World Nomads’ new underwriters reflect our unwavering commitment to providing adventurous travellers with the most comprehensive and innovative coverage available. We are thrilled to offer an enhanced travel insurance experience that addresses the unique needs of today's travellers. With features like Air Doctor and SmartDelay, our travellers can tackle today's most common travel challenges with confidence, enjoying seamless access to medical care and luxurious airport lounges during delays.”
Issued by Rein4ce on behalf of Collinson
About Collinson
Collinson Insurance: specialty lines, travel and accident & health insurance, includes underwriting capacity, insurance products and access to expert TPAs in the UK and Europe. Our deep understanding of loyalty and membership programmes enables us to offer true differentiation, so clients have confidence in our partnership to deliver growth. SmartDelay is a parametric service that ensures airline passengers who have registered their flight are given access to an airport lounge or alternative benefit, in the event of a flight delay or cancellation. Priority Pass is the world’s original and market-leading airport experiences programme. We provide travellers with access to over 1,500 airport lounges and travel experiences in over 700 airports in 145 countries.
About World Nomads
World Nomads is a fast-growing, global travel insurance company. We provide inspirational stories, safety tips and specialised travel insurance for adventurous and independent travellers. Our online travel insurance offers cover to travellers from more than 100 countries and allows you to buy and claim online, 24/7, even while already traveling.
Our travel insurance focuses on what we believe is important to travellers: emergency medical and evacuation costs, baggage, trip cancellation, trip delay and trip interruption costs. We also offer cover for more than 200 adventure sports and activities, plus tech and gear. Our policies are underwritten by a suite of specialist travel insurers that provide 24/7 emergency assistance, customer service and claims support, making us a top choice for many of the world's leading adventure, independent and youth travel brands.
World Nomads is a part of the nib Group which provides health and medical insurance to more than 1.5 million Australian and New Zealand residents. We also provide health insurance to more than 170,000 international students and workers in Australia and are Australia’s third-largest travel insurer and global distributor of travel insurance through our business nib Travel.
https://www.worldnomads.com/uk/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240627952877/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners18.11.2025 07:00:00 CET | Press release
MVM Partners joins as Avanzanite’s first institutional investor. Funding will scale Avanzanite’s existing infrastructure in all 32 countries in Europe, propel current launches, and support further product alliances and acquisitions. In just 3 years, Avanzanite has entered 3 strategic alliances and actively launched 3 rare disease medicines. Avanzanite’s Q3 2025 revenue tripled year-on-year and climbed over 20% quarter-on-quarter. Avanzanite is a unique, fully integrated partner for biotech and pharma innovators seeking to market and distribute their rare disease medicines in Europe. A new pan-European standard is being set for orphan medicine launches and patient access, with no one left behind. Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm. This press release
Over 30 Million Users Benefit From Ant International’s Bettr Credit Tech Solutions18.11.2025 04:35:00 CET | Press release
Powering the Next Wave of MSME Growth with Digital Platforms in Emerging MarketsThere was a threefold year-on-year increase in eligible customers reached through partners using Bettr's credit tech solutions by the end of October 2025.The solution features an AI-driven, alternative-data-powered credit engine that can help partner platforms to cut credit policy deployment from weeks to minutes.Partnership with Dock, a leading Brazilian payments and banking technology provider, will expand the deployment of Bettr’s credit tech solutions. Bettr, a leading provider of inclusive financial services and technology business under Ant International, today announced the launch of its proprietary tailored, one-stop credit tech solutions designed to help digital platforms build and scale their lending businesses to better serve micro, small and medium enterprises (MSMEs) in emerging markets. Bettr's credit tech solutions supported over 30 million customers to gain access to credit services through
Ant International Deepens Participation in Project Ensemble as New Architecture Community Member18.11.2025 04:00:00 CET | Press release
Ant International has been a participant in the Ensemble Sandbox since 2024 Ant International today announced it has joined Project Ensemble’s Architecture Community to support the design and advancement of Hong Kong’s tokenisation ecosystem. As a Community member, it will be more involved in defining industry standards and supporting the development of Hong Kong’s tokenisation market, together with the Hong Kong Monetary Authority (HKMA) and leading peers. A fintech representative on the Community, Ant International will also contribute its technological and innovation capabilities in tokenisation to support broader industry adoption. This comes at a time when Project Ensemble reaches a new milestone with EnsembleTX, which will see it move from sandbox experiments to live market use within a pilot environment. Through EnsembleTX, Ant International will continue to broaden its partnerships with banks and other committee members, contributing to real-world use cases of tokenisation in r
Celltrion Announces European Commission Approval of Additional Line Extension for Omlyclo™ 300mg18.11.2025 03:51:00 CET | Press release
Omlyclo™ (omalizumab) is the first and only omalizumab biosimilar approved in EuropeOmlyclo™ 300 mg/2ml prefilled syringe (PFS) presentation is now approved in EU offering a simpler dosing schedule and improved patient adherence The European Commission (EC) has granted a line extension in the European Union (EU) for Celltrion’s Omlyclo™ (omalizumab), Europe’s first and only omalizumab biosimilar, for the 300 mg/2ml prefilled syringe (PFS).The European Commission (EC) approved Omlyclo™ 75 mg/0.5ml and 150mg/1ml solution for injection in pre-filled syringe in May 2024. Omlyclo™ is indicated for the treatment of patients with allergic asthma, chronic spontaneous urticaria (CSU) and chronic rhinosinusitis with nasal polyps (CRSwNP). “The additional strength of Omlyclo™ 300mg can significantly decrease the frequency of injections, and reduce injection burden and discomfort, without compromising efficacy and safety,” said Nam Lee, Vice President of Global Medical Affairs at Celltrion. “These
2026 Mitsui Chemicals Catalysis Science Awards18.11.2025 03:00:00 CET | Press release
Online applications are open until December 25, 2025 Mitsui Chemicals, Inc. has announced that online applications for the 2026 Mitsui Chemicals Catalysis Science Award have been open since September 1, 2025. The application period will run from September 1 to December 25, 2025. Aiming to contribute to the sustainable development of chemistry and the chemical industry, Mitsui Chemicals established the Mitsui Chemicals Catalysis Science Awards in 2004. The awards consist of the Catalysis Science Award and the Catalysis Science Award for Creative Work, which recognize outstanding achievements in the field of catalysis science. To date, the awards have been conferred on 33 researchers within Japan and overseas. Past recipients include individuals who have gone on to be highly acclaimed worldwide, receiving honors such as the Nobel Prize in Chemistry and other prestigious Japanese and international awards. We welcome applications from a wide range of R&D fields, including solid catalysts,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom